Whipplewood Advisors LLC Purchases Shares of 516 Intuitive Surgical, Inc. (NASDAQ:ISRG)

Whipplewood Advisors LLC acquired a new position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 516 shares of the medical equipment provider's stock, valued at approximately $269,000.

Several other institutional investors have also recently made changes to their positions in the company. Berbice Capital Management LLC purchased a new stake in shares of Intuitive Surgical during the 4th quarter worth about $26,000. BankPlus Trust Department acquired a new position in Intuitive Surgical in the 4th quarter worth about $28,000. MidAtlantic Capital Management Inc. purchased a new position in Intuitive Surgical during the third quarter worth approximately $33,000. Decker Retirement Planning Inc. acquired a new stake in Intuitive Surgical in the fourth quarter valued at approximately $36,000. Finally, Capital Performance Advisors LLP purchased a new stake in shares of Intuitive Surgical in the third quarter valued at approximately $38,000. 83.64% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Intuitive Surgical

In other Intuitive Surgical news, Director Amal M. Johnson sold 4,635 shares of Intuitive Surgical stock in a transaction dated Tuesday, January 28th. The stock was sold at an average price of $566.60, for a total value of $2,626,191.00. Following the completion of the transaction, the director now directly owns 12,275 shares of the company's stock, valued at $6,955,015. The trade was a 27.41 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Jamie Samath sold 270 shares of the stock in a transaction dated Tuesday, December 10th. The stock was sold at an average price of $540.15, for a total transaction of $145,840.50. Following the sale, the chief financial officer now directly owns 8,757 shares in the company, valued at $4,730,093.55. This represents a 2.99 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 8,077 shares of company stock worth $4,620,025. 0.80% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

ISRG has been the subject of several research analyst reports. Truist Financial upped their price target on shares of Intuitive Surgical from $640.00 to $666.00 and gave the stock a "buy" rating in a research report on Friday, January 24th. UBS Group raised their target price on Intuitive Surgical from $500.00 to $560.00 and gave the company a "neutral" rating in a research report on Monday, January 27th. Bernstein Bank boosted their price target on Intuitive Surgical from $655.00 to $700.00 and gave the stock an "overweight" rating in a research report on Monday, January 27th. Royal Bank of Canada increased their price objective on Intuitive Surgical from $611.00 to $641.00 in a research note on Monday, January 27th. Finally, Citigroup lifted their target price on shares of Intuitive Surgical from $640.00 to $711.00 and gave the stock a "buy" rating in a research note on Friday, January 24th. One analyst has rated the stock with a sell rating, five have given a hold rating and sixteen have given a buy rating to the company. According to MarketBeat, Intuitive Surgical presently has an average rating of "Moderate Buy" and a consensus price target of $613.10.

Intuitive Surgical Trading Up 1.7 %

ISRG traded up $9.38 on Friday, hitting $573.15. The company had a trading volume of 2,399,758 shares, compared to its average volume of 1,733,598. The company's fifty day moving average price is $569.87 and its 200 day moving average price is $528.64. Intuitive Surgical, Inc. has a 1 year low of $364.17 and a 1 year high of $616.00. The firm has a market cap of $204.14 billion, a P/E ratio of 89.42, a PEG ratio of 5.85 and a beta of 1.39.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.